Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a jolt and setting up future registrational trials for the serotonin receptor ...
Bright Minds (DRUG) Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients ...
The Phase 2 open-label, multicenter study evaluated safety, tolerability and efficacy of BMB-101 in adults with drug-resistant Absence Seizures and DEE. A total of 24 patients were enrolled, exceeding ...
BMB Group is one of the world’s most exclusive financial institutions. Its growing numbers of investors are often drawn from eastern ruling families with vast riches gleaned from the long-term growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results